Thus, it was reported that MMR deficiency does not lead to clinical resistance to TMZ in gliomas [158], while a study published later showed that even small changes in the expression of MSH2 have an influence on TMZ sensitivity and thus, the therapeutic success [159]. The gene discussed is MRC1; the disease is central nervous system cancer.